【Nippon Kayaku】Manufacturing and Sales Approval Transfer Agreement Signed ｜ May 2026

Overview of Business Activities

Nippon Kayaku has signed a transfer agreement with AstraZeneca regarding the manufacturing and sales approval of "Zoladex® 3.6mg Depot / LA 10.8mg Depot." This allows Nippon Kayaku, which has an extensive track record and a solid foundation in the oncology field, to succeed the drug, aiming to optimize its lifecycle and maintain a long-term supply system. The specific timing of the transfer will be announced once finalized. This has already been incorporated into the earnings forecast for the fiscal year ending March 2027, announced on May 12, 2026, and will not impact the current fiscal year's performance.

Future Outlook and Impact on Investors

By signing this agreement, Nippon Kayaku will strengthen the stability of product supply and long-term business development in the oncology sector. While the specific timing of the transfer and market conditions may lead to long-term effects in the future, there is currently no impact on the earnings forecast for the fiscal year ending March 2027. Details of further developments will be disclosed in due course. For investors, this move signifies stability in the business and aligns with the company's long-term growth strategy.